TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Sab Biotherapeutics, Inc.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two decades of experience in biopharmaceutical development and clinical strategy. Both appointments are intended to support the company's advancement of SAB-142, its lead candidate for Type 1 Diabetes treatment, through clinical development and potential commercialization.

Insights
RBSFY   negative

Mentioned as an ancillary party to the anticompetitive allegations

SABS   positive

The appointment of experienced executives with strong track records in biotech leadership and drug development signals confidence in the company's direction and potential. Zaccardelli's success with major product launches and Jain's expertise in autoimmune disease development strengthen the company's leadership for advancing SAB-142 through clinical trials and commercialization, indicating positive momentum for the company's growth trajectory.

Keywords
#board appointments #Type 1 Diabetes #SAB-142 #clinical-stage biopharmaceutical #autoimmune disease #drug development #commercialization

Tickers
SABS SABSW
← Prev: CECO Environmental Announces Upcoming Investor Conference